Loading
Latest filing published 12 May 2023 for Ampio Pharmaceuticals, Inc., €4,926.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David R. Stevens discloses dealings in Ampio Pharmaceuticals, Inc. to SEC (Form 4). We count 9 filings; the first trade dates from 4 January 2016 and the latest from 12 May 2023.
No open-market sale appears; the market trades are 3 purchases worth €19k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 6 share grants. Since January 2023: 3 purchases and no sales on the market.
A typical purchase (the median) is worth €5,040. No cluster: in 3 purchases, no other insider of the company bought within 30 days. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 0% of cases; the median change was -18.3%. These figures describe past trades and do not predict future prices.
The latest filing, published on 12 May 2023, reports an open-market purchase of €4,926 in Ampio Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations